Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells

• Material Type: 博士論文
• Title: Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells
• Author/Editor: Otsuka, Kenji; Mitsuhashi, Atsushi; Goto, Hisatsugu; Hanibuchi, Masaki; Koyama, Kazuya; Ogawa, Hirohisa; Ogino, Hirokazu; Saijo, Atsuro; Kozai, Hiroyuki; Yoneda, Hiroto; Tobiume, Makoto; Kishuku, Masatoshi; Ishizawa, Keisuke; Nishioka, Yasuhiko
• Author Heading: Otsuka, Kenji; Mitsuhashi, Atsushi; Goto, Hisatsugu; Hanibuchi, Masaki; Koyama, Kazuya; Ogawa, Hirohisa; Ogino, Hirokazu; Saijo, Atsuro; Kozai, Hiroyuki; Yoneda, Hiroto; Tobiume, Makoto; Kishuku, Masatoshi; Ishizawa, Keisuke; Nishioka, Yasuhiko
• Publication, Distribution, etc.: Elsevier
• Publication Date: 2020-05-21
• Publication Date (W3CDTF): 2020-05-21
• Alternative Title: 抗PD-1抗体への化学療法の併用はmyeloid-derived suppressor cellsを減少させることにより中皮腫の増殖を抑制する
• Periodical title: Lung Cancer
• No. or year of volume/issue: 146
• Volume: 146
• Pages: 86-96
• ISSN (Periodical Title): ISSN : 0169-5002
• Degree grantor/type: 徳島大学
• Date Granted: 2020-09-24
• Dissertation Number: 甲第3457号
• Degree Type: 博士（医学）
• Text Language Code: eng
• Subject Heading: Lung cancer; Malignant pleural mesothelioma; PD-1; MDSC; VEGF
• Target Audience: 一般
• Note (General): Background: The combination of anti-PD-1/PD-L1 antibody with chemotherapy has been approved for the first-line therapy of lung cancer. However, the effects against malignant mesothelioma (MPM) and the immunological mechanisms by which chemotherapy enhances the effect of targeting PD-1/PD-L1 in MPM are poorly understood. Materials and Methods: We utilized syngeneic mouse models of MPM and lung cancer and assessed the therapeutic effects of anti-PD-1 antibody and its combination with cisplatin (CDDP) and pemetrexed (PEM). An immunological analysis of tumor-infiltrating cells was performed with immunohistochemistry. Results: We observed significant therapeutic effects of anti-PD-1 antibody against MPM. Although the effect was associated with CD8+ and CD4+ T cells in tumors, the number of Foxp3+ cells was not reduced but rather increased. Consequently, combination with CDDP/PEM significantly enhanced the antitumor effects of anti-PD-1 antibody by decreasing numbers of intratumoral myeloid-derived suppressor cells (MDSCs) and vessels probably through suppression of VEGF expression by CDDP+PEM. Conclusions: The combination of anti-PD-1 antibody with CDDP+PEM may be a promising therapy for MPM via inhibiting the accumulation of MDSCs and vessels in tumors.
• Format (IMT): application/pdf
• Access Restrictions: インターネット公開
• Related Material (DOI): 10.1016/j.lungcan.2020.05.023
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 徳島大学 : 徳島大学機関リポジトリ

Table of Contents

http://repo.lib.tokushima-u.ac.jp/files/public/11/115324/20201007151918640854/k3457_abstract_review.pdf fulltext

http://repo.lib.tokushima-u.ac.jp/files/public/11/115324/2020100815142996924/k3457_fulltext.pdf fulltext